Br J Cancer: Retrospective queue study for Vismodegib treatment of patients with advanced and multiple substrate cell carcinoma

Substrate cell carcinoma (BCC) is one of the most common skin cancers in the world.
treatment options vary from non-invasive therapy to topical radiotherapy and surgery.
If left untreated, the disease develops into advanced BCC (aBCC), including local late BCC (laBCC) and metastasis BCC (mBCC), and surgery or radiotherapy is not effective for aBCC.
since 2011, Vismodegib has been used to treat laBCC and mBCC, and most of the efficacy and safety data are provided by clinical trials.
the study aims to assess the efficacy of vismodegib in treating patients with laBCC, mBCC, and substrate cellular syndrome (BCNS), as well as tumor characteristics that are more likely to be fully mitigated.
reviewed queue study on the efficacy assessment of local late-stage cell carcinoma included all histologically proven ≥ 18-year-olds in the Netherlands from July 2011 to September 2019 who received ≥1 doses of movisdegib between July 2011 and September 2019.
Kaplan-Meier curve analysis of the time-to-event time of each treatment included a total of 48 laBCC, 11 mBCC and 19 BCNS patients.
results showed that the medium non-progressed survival of laBCC patients was 10.3 months, mBCC patients were 11.7 months, and BCNS patients were 19.1 months.
larger laBCC corresponds to a lower full mitigation rate.
63 percent of all BNS patients received vismodegib≥2 treatment, and all received partial responses.
, the results showed that half of the patients in the group had progressed in treatment within a year of using vismodegib.
and more research data are needed to study vismodegib's other treatment strategies and assess the long-term effects of repeated vismodegib therapy.